-
Document de presse | 2020.05.26
MV-SARS-CoV-2 vaccine candidate: a new partnership between Institut Pasteur, CEPI, Thémis and MSD
Institut Pasteur announces recent advances in the development of one of its candidate vaccines, MV-SARS-CoV-2, using the measles vector, as part of a renewed partnership with CEPI and the companies Thémis and MSD.With over 100 vaccine projects in development worldwide, the development of a vaccine against SARS CoV-2 infection remains a challenge, with many scientific uncertainties ahead. The...
-
Article | 2020.10.14
Covid-19: vaccine against SARS-CoV-2 infection, using the measles vector
Phase I testing in humans for the Institut Pasteur's SARS-CoV-2 vaccine candidate using the measles vector was lauchned in August 2020 in France and Belgium. Following the intermediate results of the Phase I clinical trial, the Institut Pasteur is stopping (January, 2021) development of the vaccine candidate based on the measles platform.
-
News | 2020.11.24
Yellow fever: risk of virus transmission in the Asia-Pacific region
A study, the most comprehensive assessment of vector competence, shows that Aedes aegypti mosquitoes from the Asia-Pacific region are capable of transmitting yellow fever virus. This indicates that vector populations are seemingly not a brake to the emergence of yellow fever in the region.Viral pathogens with high epidemic potential have been historically a major concern for human health. Large-...
-
Article | 2019.08.06
Vaccinology and Immunotherapy Initiative: Innovation – Vaccine Candidates
The Institut Pasteur has a distinguished history of vaccine development as a means to improve global health. A stronghold of the Institut Pasteur in vaccines is the development of novel technologies for vaccine design and delivery with several candidates currently under clinical evaluation, either licensed to development and commercialization partners or under Institut Pasteur sponsorship.
-
Fiche maladie | 2019.10.16
Chikungunya
Chikungunya is a viral disease transmitted to humans by the bite of Aedes albopictus and Aedes aegypti mosquitoes. Although rarely fatal, chikungunya can cause significant pain and debilitating symptoms that affect patients' quality of life. Existing treatments are solely symptomatic. In France, the current conditions in 80% of départements are conducive to the emergence of chikungunya.
-
Fiche maladie | 2015.10.06
Yellow fever
Yellow fever is a viral disease that was first described in the mid-sixteenth century in Yucatán, Mexico. It is caused by yellow fever virus, an arbovirus (a virus transmitted by an insect vector) isolated in 1927, simultaneously in Ghana and at the Institut Pasteur de Dakar, Senegal. The disease is endemic in Africa and in Central and South America. The case fatality rate is high, fluctuating...
-
News | 2016.12.08
Congratulations are in order for the Pasteur iGEM 2016 team!
On Friday December 9 this year, the 19 students* in the Pasteur iGEM 2016 team receive their awards at a ceremony that took place in the Institut Pasteur’s Duclaux lecture hall in Paris. For the second consecutive year the team excelled in the iGEM (international Genetically Engineered Machine) competition, an annual event to promote research in synthetic biology. The team returned from the...
-
Document de presse | 2017.02.24
Link between a virus and sexual reproduction on Earth
By formally identifying the main player in the fusion between male and female sex cells, researchers from the Institut Pasteur, the CNRS and Paris Descartes University, together with American and German teams, have revealed the probable viral origin of this fusion process, which is common to a vast number of living organisms on Earth. In addition, the study provides new lines of research for...
-
News | 2017.06.22
A strategy for attenuating a virus by modifying its evolutionary potential
RNA viruses, like influenza viruses, have broad genetic variability, which gives them a high adaptive potential. As part of the fight against RNA viruses, scientists at the Institut Pasteur – evolutionary virologists – decided to alter their future. Along with colleagues from Lund University (Sweden), they succeeded in altering the genomes of an enterovirus and an influenza virus, thereby...
-
Document de presse | 2017.08.31
Gut microbiota of mosquito larvae has an impact on adult insect’s ability to transmit human pathogens
Researchers from the Institut Pasteur and CNRS, in collaboration with scientific teams from IRD, University Claude Bernard Lyon 1*, and CIRMF in Gabon, have demonstrated that differential bacterial exposure during the development of mosquito larvae (Aedes aegypti) can have “carry-over” effects on adult traits related to an insect’s ability to be a successful vector of arboviruses. These results...
